GlassScriptPhysician profile
Padma Khanchustambham
NPI 1245243146
$3,204.52
in general payments reported to CMS, 2019-2025
29 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $885 · 2021: $390 · 2022: $240 · 2023: $219 · 2024: $408 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $482.38 | 2019-2025 | Wegovy |
| Glaxosmithkline, LLC. | $302.59 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $297.99 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $271.07 | 2019-2025 | Capvaxive, Belsomra, Steglatro |
| Amgen INC. | $194.82 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $182.69 | 2019-2024 | |
| Allergan, INC. | $182.29 | 2019-2020 | |
| Abbvie INC. | $170.50 | 2019-2024 | |
| Boston Scientific Corporation | $135.02 | 2022 | |
| Lilly USA, LLC | $122.51 | 2020-2024 | Mounjaro |
| Mylan Specialty L.P. | $110.82 | 2020-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $107.51 | 2019-2020 | |
| Amarin Pharma, INC. | $103.07 | 2020-2021 | |
| Sanofi Pasteur INC. | $95.64 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.24 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $45.67 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $43.63 | 2019-2024 | Zoryve |
| Astellas Pharma US INC | $37.39 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.40 | 2020-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $31.53 | 2024 | |
| Exact Sciences Corporation | $29.94 | 2023 | Cologuard Collection Kit |
| Averitas Pharma INC. | $27.76 | 2025 | Qutenza |
| Viatris Specialty LLC | $26.03 | 2025 | Yupelri |
| Esperion Therapeutics, INC. | $24.66 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.46 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $21.21 | 2021 | |
| Ibsa Pharma INC. | $18.78 | 2021 | |
| Sumitomo Pharma America, INC. | $14.78 | 2024 | Gemtesa |
| Alfasigma USA, INC. | $13.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Padma Khanchustambham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.